Elevai Labs Inc. Subsidiary, Elevai Skincare, Announces The Elevai S-Series Hair and Scalp Care Product Line
June 28 2024 - 9:00AM
ELEVAI LABS, INC. (NASDAQ: ELAB), a pioneering force in
medical aesthetics, is excited to announce the introduction of the
Elevai S-Series™ hair and scalp care product line through Elevai
Skincare, a subsidiary of Elevai Labs.
The Elevai S-series Root Renewal System™ and the
technology behind it will be presented at The Aesthetic Show on
June 28th, 2024, held at the Wynn Las Vegas, NV.
The Elevai S-Series Root Renewal SystemTM
is a three-part hair and scalp care system that utilizes a
first-in-class dual mechanism powered by exosomes and mitochondrial
technology that incorporates Elevai’s proprietary PREx™ (“Precision
Regenerative Exosome Technology”) and Yuva Bioscience’s Y100
mitochondrial technology. This innovative combination is designed
to address common scalp and hair care concerns, such as the
appearance of thinning hair, by promoting scalp and hair vitality.
The product line is formulated to be easy to use, cost-effective,
and scientifically backed, offering a new solution for men and
women experiencing hair loss and thinning hair.
The Y100 mitochondrial technology was identified
using Yuva’s advanced artificial intelligence (“AI”) platform,
“MitoGPT” which was co-developed by Yuva Biosciences’s Chief
Scientific Officer, Keshav K. Singh, PhD and key advisor for AI,
Jeb Linton, an IBM data scientist. Dr. Singh is known for studies
he published on mitochondria, most notably his 2018 research
demonstrating mitochondrial dysfunction is a key cause of aging for
hair and skin in mice, and can be reversed.
"The Elevai S-Series represents a natural
progression from our current facial topical exosome formulations,"
says Dr. Jordan R. Plews, PhD, the CEO of ELEVAI Skincare. "There
is a strong movement towards the 'skinification' of the hair and
scalp. With our three-part hair and scalp care system, we are
expanding options for men and women looking for an easy-to-use,
cost-effective solution backed by scientific research. By joining
forces with Yuva Biosciences, we’ve formulated first-in-class
products that we believe can positively impact the most common
scalp and hair care concerns associated with the appearance of
thinning hair," concluded Dr. Plews.
The Elevai S-Series will eventually become
available through the Company’s US sales representative and through
the company’s website, www.ElevaiSkincare.com.
About Elevai Labs, Inc.:
Elevai Labs Inc. (NASDAQ: ELAB) specializes in
medical aesthetics and biopharmaceutical drug development, focusing
on innovations for skin aesthetics and treatments tied to obesity
and metabolic health. Driven by a commitment to scientific
research, we aim to transform personal health and beauty. For more
information, please visit www.elevailabs.com.
About Elevai Skincare,
Inc.:
Elevai Skincare Inc., an Elevai Labs company, is
a medical aesthetics company developing and commercializing
cutting-edge physician-dispensed skin and hair care applications.
Elevai develops cosmetic products for the physician-dispensed
market, with a focus on leveraging novel proprietary science-backed
technologies, including its stem cell exosome technology. For more
information, please visit www.elevaiskincare.com.
About Yuva Biosciences:
Yuva Biosciences is a longevity company
harnessing the cutting edge of mitochondrial science to help
consumer brands develop products targeted at aging-related hair
loss, wrinkled skin, and many other symptoms of aging. Yuva
Biosciences is headquartered in Birmingham, Alabama. For more
information, please visit www.yuvabio.com.
Forward-Looking Statements
Statements contained in this press release
regarding matters that are not historical facts are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended. Words such as
“believes,” “expects,” “plans,” “potential,” “would” and “future”
or similar expressions such as “look forward” are intended to
identify forward-looking statements. Although the Company believes
that the expectations expressed in these forward-looking statements
are reasonable, it cannot assure you that such expectations will
turn out to be correct, and the Company cautions investors that
actual results may differ materially from the anticipated results.
These and other risks are described more fully in Elevai’s filings
with the Securities and Exchange Commission (“SEC”), including the
“Risk Factors” section of the Company’s Annual Report on Form 10-K
for the year ended December 31, 2023, filed with the SEC on March
29, 2024, and its other documents subsequently filed with or
furnished to the SEC. All forward-looking statements contained in
this press release speak only as of the date on which they were
made. Except to the extent required by law, the Company undertakes
no obligation to update such statements to reflect events that
occur or circumstances that exist after the date on which they were
made.
Media Contact
Makenzie Mann
contact@elevailabs.com
Elevai Labs (NASDAQ:ELAB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Elevai Labs (NASDAQ:ELAB)
Historical Stock Chart
From Jul 2023 to Jul 2024